Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer

福尔菲里 伊立替康 医学 贝伐单抗 内科学 中性粒细胞减少症 奥沙利铂 结直肠癌 化疗 氟尿嘧啶 发热性中性粒细胞减少症 肿瘤科 胃肠病学 外科 癌症
作者
Yuki Matsubara,Toshiki Masuishi,Takatsugu Ogata,Taiko Nakazawa,Kyoko Kato,Kazuki Nozawa,Yukiya Narita,Kazunori Honda,Hideaki Bando,Hiroya Taniguchi,Shigenori Kadowaki,Masashi Ando,Masahiro Tajika,Kei Muro
出处
期刊:Journal of Cancer Research and Clinical Oncology [Springer Science+Business Media]
卷期号:149 (3): 1123-1129 被引量:1
标识
DOI:10.1007/s00432-022-03979-2
摘要

Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin. However, the benefits of incorporating fluoropyrimidines into second-line chemotherapy for patients with mCRC who are refractory to fluoropyrimidines are unknown. We retrospectively evaluated patients with mCRC who were administered irinotecan plus bevacizumab or FOLFIRI plus bevacizumab as second-line chemotherapy at a single institution from January 2010 to April 2020. We compared the efficacy and safety of irinotecan plus bevacizumab (IRI group) with those of FOLFIRI plus bevacizumab (FOLFIRI group). Of the 255 enrolled patients, 107 (IRI/FOLFIRI group, 31/76 patients) were eligible for analysis. After a median follow-up of 13.1 months (range 1.2–48.4) and 14.3 months (range 0.9–46.5) for the IRI and FOLFIRI groups, respectively, the median progression-free survival was 6.4 months and 5.8 months [adjusted hazard ratio (aHR), 0.82; 95% confidence interval (CI) 0.50–1.34, p = 0.44] and the median overall survival was 16.6 months and 16.5 months (aHR, 1.01; 95% CI 0.59–1.69; p = 0.97) in the IRI and FOLFIRI groups, respectively. All-grade nausea, stomatitis, neutropenia, thrombocytopenia, Grade 3/4 neutropenia, and febrile neutropenia occurred more frequently in the FOLFIRI group than in the IRI group. Our study suggests omitting fluorouracil from FOLFIRI plus bevacizumab as the second-line chemotherapy decreases adverse events without affecting the treatment efficacy in patients with mCRC who are refractory to fluoropyrimidines. Further randomized prospective studies are warranted to validate our result.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CipherSage应助青野采纳,获得10
刚刚
无语的沛春完成签到,获得积分10
刚刚
wxp19发布了新的文献求助20
刚刚
tianya完成签到,获得积分10
1秒前
完美世界应助sunshine采纳,获得10
1秒前
科研通AI2S应助马er采纳,获得10
2秒前
skbkbe完成签到,获得积分10
2秒前
2秒前
CAOHOU应助酷酷银耳汤采纳,获得10
2秒前
3秒前
6秒前
高贵梦露发布了新的文献求助10
8秒前
10秒前
11秒前
GL发布了新的文献求助10
11秒前
乐乐应助如意枫叶采纳,获得10
11秒前
12秒前
史念薇发布了新的文献求助10
12秒前
xixi完成签到 ,获得积分10
12秒前
14秒前
青野发布了新的文献求助10
16秒前
19秒前
20秒前
高贵梦露完成签到,获得积分10
20秒前
22秒前
24秒前
量子星尘发布了新的文献求助10
25秒前
如意枫叶发布了新的文献求助10
26秒前
26秒前
27秒前
27秒前
29秒前
30秒前
31秒前
赘婿应助GL采纳,获得10
31秒前
32秒前
32秒前
Archer宇完成签到,获得积分10
32秒前
狸花小喵发布了新的文献求助10
34秒前
科研废物完成签到 ,获得积分10
34秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136